anastrozole has been researched along with Aging in 6 studies
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Roelfsema, F | 1 |
| Yang, RJ | 1 |
| Takahashi, PY | 1 |
| Erickson, D | 1 |
| Bowers, CY | 1 |
| Veldhuis, JD | 1 |
| Dias, JP | 1 |
| Melvin, D | 1 |
| Simonsick, EM | 1 |
| Carlson, O | 1 |
| Shardell, MD | 1 |
| Ferrucci, L | 1 |
| Chia, CW | 1 |
| Basaria, S | 1 |
| Egan, JM | 1 |
| Burnett-Bowie, SA | 1 |
| McKay, EA | 1 |
| Lee, H | 1 |
| Leder, BZ | 2 |
| Rohrer, JL | 1 |
| Rubin, SD | 1 |
| Gallo, J | 1 |
| Longcope, C | 1 |
| Cherrier, MM | 1 |
| Matsumoto, AM | 1 |
| Amory, JK | 1 |
| Ahmed, S | 1 |
| Bremner, W | 1 |
| Peskind, ER | 1 |
| Raskind, MA | 1 |
| Johnson, M | 1 |
| Craft, S | 1 |
| Lea, CK | 1 |
| Flanagan, AM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Anastrozole Administration in Elderly Hypogonadal Men[NCT00136695] | Phase 2 | 88 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| Role of Testosterone and Its Metabolites Regarding Different Physiological Functions in Subjects Affected by Gender Identity Disorder (FtM Transsexuals)[NCT00146146] | Phase 3 | 15 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Testosterone Supplementation in Men With MCI[NCT00539305] | Phase 3 | 22 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00136695)
Timeframe: Baseline and 1 year
| Intervention | grams (Mean) |
|---|---|
| Anastrozole | -2000 |
| Placebo | -1500 |
Values represent self evaluation of vigor-activity. The scale compares t-scores of participants to published norms (range 0-100), and higher scores indicate elevated emotion in subscale. Higher t-scores in vigor-activity subscale are considered favorable. Month 3 and Month 6 values display change from baseline. (NCT00539305)
Timeframe: Baseline, 3 and 6 months
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Month 3 (Change from Baseline) | Month 6 (Change from Baseline) | |
| Placebo Group | 55.5 | -0.1 | -0.5 |
| Treatment Group | 57.7 | -4.5 | 1.9 |
Values represent total score in Long Delay Word List Recall. Higher score indicates higher level of functioning (range 0-15). Month 3 and Month 6 indicate change from baseline. (NCT00539305)
Timeframe: Baseline, 3 and 6 months
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Month 3 (Change from Baseline) | Month 6 (Change from Baseline) | |
| Placebo Group | 4.9 | 0.0 | 1.5 |
| Treatment Group | 6.2 | 2.3 | 0.9 |
Values represent self evaluation of depression (range 0-30). Higher scores indicate a more depressed mood. Month 3 and Month 6 indicate change from baseline. (NCT00539305)
Timeframe: Baseline, Month 3, Month 6
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Month 3 (Change from Baseline) | Month 6 (Change from Baseline) | |
| Placebo Group | 4.1 | 2.3 | 2.7 |
| Treatment Group | 7.2 | 0.7 | -2.8 |
Self assessment of Physical Functioning in Health Survey. Higher scores indicate a higher level of functioning (range 0-100). Month 3 and 6 values represent change from baseline in subscale. (NCT00539305)
Timeframe: Baseline, Month 3, Month 6
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Month 3 (Change from Baseline) | Month 6 (Change from Baseline) | |
| Placebo Group | 85.6 | -3.8 | -5.4 |
| Treatment Group | 70.7 | 15.0 | 6.4 |
5 trials available for anastrozole and Aging
| Article | Year |
|---|---|
Aromatized Estrogens Amplify Nocturnal Growth Hormone Secretion in Testosterone-Replaced Older Hypogonadal Men.
Topics: Administration, Cutaneous; Adult; Aged; Aging; Anastrozole; Aromatase; Aromatase Inhibitors; Circadi | 2018 |
Effects of aromatase inhibition vs. testosterone in older men with low testosterone: randomized-controlled trial.
Topics: Aged; Aged, 80 and over; Aging; Anastrozole; Aromatase; Aromatase Inhibitors; Body Composition; Bone | 2016 |
Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels.
Topics: Aged; Aging; Anastrozole; Aromatase Inhibitors; Biomarkers; Bone and Bones; Bone Density; Double-Bli | 2009 |
Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels.
Topics: Aged; Aging; Anastrozole; Aromatase Inhibitors; Enzyme Inhibitors; Estrogens; Humans; Hypogonadism; | 2004 |
The role of aromatization in testosterone supplementation: effects on cognition in older men.
Topics: Aged; Aged, 80 and over; Aging; Anastrozole; Aromatase; Aromatase Inhibitors; Double-Blind Method; E | 2005 |
The role of aromatization in testosterone supplementation: effects on cognition in older men.
Topics: Aged; Aged, 80 and over; Aging; Anastrozole; Aromatase; Aromatase Inhibitors; Double-Blind Method; E | 2005 |
The role of aromatization in testosterone supplementation: effects on cognition in older men.
Topics: Aged; Aged, 80 and over; Aging; Anastrozole; Aromatase; Aromatase Inhibitors; Double-Blind Method; E | 2005 |
The role of aromatization in testosterone supplementation: effects on cognition in older men.
Topics: Aged; Aged, 80 and over; Aging; Anastrozole; Aromatase; Aromatase Inhibitors; Double-Blind Method; E | 2005 |
1 other study available for anastrozole and Aging
| Article | Year |
|---|---|
Physiological plasma levels of androgens reduce bone loss in the ovariectomized rat.
Topics: Aging; Anastrozole; Androgen Antagonists; Androstenedione; Anilides; Animals; Body Weight; Bone Reso | 1998 |